Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1613020

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1613020

Cluster Headache Market by Cluster Headaches Type, Drug Type, Route of Administration, Distribution Channel - Global Forecast 2025-2030

PUBLISHED:
PAGES: 187 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Cluster Headache Market was valued at USD 381.04 million in 2023, expected to reach USD 401.80 million in 2024, and is projected to grow at a CAGR of 5.71%, to USD 562.38 million by 2030.

Cluster headaches are a neurological disorder characterized by severe, recurring pain in one side of the head, often around the eye. The scope of research and market analysis on cluster headaches involves understanding the necessity of effective treatments, their application in medical practice, and their end-use scope, which primarily includes pharmaceutical companies, healthcare providers, and patients. The demand for treatment solutions is driven by the rising prevalence of the disorder and the debilitating impact on patient quality of life. Key factors influencing market growth include advancements in neurological research, increasing awareness, and improving healthcare infrastructure. Innovative treatments like non-invasive neurostimulation and novel pharmaceutical formulations present emerging opportunities, driven by ongoing clinical trials and regulatory approvals. However, challenges such as high costs of novel treatments, limited patient access in developing regions, and the complexity of accurately diagnosing this rare condition pose significant market barriers. To harness potential opportunities, stakeholders should focus on partnerships between biotech firms and research institutions to accelerate R&D, investing in public awareness campaigns, and expanding accessibility through generic drug development. A concentrated effort on personalized medicine and exploring the genetic predispositions associated with cluster headaches may also unlock unexplored market potentials. While innovation is currently directed towards targeted drug therapies and technological integration, a deeper exploration into non-pharmaceutical interventions, such as lifestyle modifications and integrative therapies, could diversify treatment pipelines. The competitive landscape remains moderately concentrated, with established pharmaceutical giants, like GlaxoSmithKline, vying against emerging biotech firms. Ultimately, the cluster headache market is poised for growth, driven by unmet clinical needs and evolving treatment paradigms, but overcoming economic and educational constraints remains crucial for achieving equitable market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 381.04 million
Estimated Year [2024] USD 401.80 million
Forecast Year [2030] USD 562.38 million
CAGR (%) 5.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cluster Headache Market

The Cluster Headache Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cluster headaches worldwide
    • Ongoing research and development initiatives in pharmaceuticals and medical technology
    • Surging healthcare investments to advance treatment options
  • Market Restraints
    • Low awareness or misdiagnosis of cluster headaches
  • Market Opportunities
    • Advancements in personalized medicines tailored to individual patient genetics
    • Ongoing product approvals for newly developed cluster headache drugs
  • Market Challenges
    • Complex regulatory requirements for product approvals

Porter's Five Forces: A Strategic Tool for Navigating the Cluster Headache Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cluster Headache Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cluster Headache Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cluster Headache Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cluster Headache Market

A detailed market share analysis in the Cluster Headache Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cluster Headache Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cluster Headache Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cluster Headache Market

A strategic analysis of the Cluster Headache Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cluster Headache Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca plc, Biogen, Inc., Boehringer Ingelheim International GmbH, electroCore, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Lundbeck LLC, Lupin Limited, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cluster Headache Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cluster Headaches Type, market is studied across Chronic Cluster Headaches and Episodic Cluster Headaches.
  • Based on Drug Type, market is studied across Anti-Seizure Drugs, Calcium Channel Blockers, Corticosteroids, Ergots, Lithium carbonate, Melatonin, and Sumatriptan.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-CA100284D080

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cluster headaches worldwide
      • 5.1.1.2. Ongoing research and development initiatives in pharmaceuticals and medical technology
      • 5.1.1.3. Surging healthcare investments to advance treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Low awareness or misdiagnosis of cluster headaches
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in personalized medicines tailored to individual patient genetics
      • 5.1.3.2. Ongoing product approvals for newly developed cluster headache drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory requirements for product approvals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cluster Headaches Type: Increasing need for drugs to treat chronic cluster headache
    • 5.2.2. Distribution Channel: Rising preference for online pharmacies for effective product penetration
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cluster Headache Market, by Cluster Headaches Type

  • 6.1. Introduction
  • 6.2. Chronic Cluster Headaches
  • 6.3. Episodic Cluster Headaches

7. Cluster Headache Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Anti-Seizure Drugs
  • 7.3. Calcium Channel Blockers
  • 7.4. Corticosteroids
  • 7.5. Ergots
  • 7.6. Lithium carbonate
  • 7.7. Melatonin
  • 7.8. Sumatriptan

8. Cluster Headache Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Topical

9. Cluster Headache Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Cluster Headache Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cluster Headache Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cluster Headache Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Amgen Expands Therapeutic Portfolio Through Strategic Acquisition of Horizon Therapeutics
    • 13.3.2. Tonix Pharmaceuticals Expands Migraine Treatment Portfolio with Strategic Acquisition
    • 13.3.3. FDA Approval of QULIPTA for Treatment of Chronic and Episodic Migraine
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca plc
  • 4. Biogen, Inc.
  • 5. Boehringer Ingelheim International GmbH
  • 6. electroCore, Inc.
  • 7. Eli Lilly and Company
  • 8. GlaxoSmithKline PLC
  • 9. Lundbeck LLC
  • 10. Lupin Limited
  • 11. Pfizer Inc.
  • 12. Sun Pharmaceutical Industries Ltd.
  • 13. Teva Pharmaceutical Industries Ltd.
Product Code: MRR-CA100284D080

LIST OF FIGURES

  • FIGURE 1. CLUSTER HEADACHE MARKET RESEARCH PROCESS
  • FIGURE 2. CLUSTER HEADACHE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLUSTER HEADACHE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLUSTER HEADACHE MARKET DYNAMICS
  • TABLE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CHRONIC CLUSTER HEADACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EPISODIC CLUSTER HEADACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-SEIZURE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY LITHIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY MELATONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY CLUSTER HEADACHES TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!